TNDM
Tandem Diabetes Care, Inc.
Healthcare · Medical - Devices
Undervalued·Quality 70·RSI 33·DCF -350%·Conviction 70
Investment Thesis — Tandem Diabetes Care, Inc.
The market misprices Tandem as a hardware-centric medical device company, overlooking its evolving position as a sticky, integrated diabetes management platform. While recent returns reflect a nascent re-evaluation, the full value of its ecosystem and recurring revenue potential remains significantly underappreciated.
Catalysts
- Successful launch and rapid adoption of the new t:slim X2 Mobi pump
- Expanded insurance coverage or favorable reimbursement changes for Control-IQ technology
- Strong international market share gains and geographic expansion
Risk Factors
- Intensified competition from rival integrated diabetes management systems
- Regulatory hurdles or delays for new product approvals and market access
- Challenges in securing or maintaining favorable reimbursement policies
Key Debates
TNDM exceeds 17.5% FY24 revenue growth by Q3.
Gross margins expand 200bps by H1 FY25 from product mix.
TNDM reaches $25.56 PT by Q4 2024 on growth acceleration.